Please use this identifier to cite or link to this item:
Title: Double-Blind, Placebo-Controlled Study of Lurasidone Monotherapy for the Treatment of Bipolar I Depression
Author: Kato, Tadafumi
Ishigooka, Jun
Miyajima, Mari
Watabe, Kei
Fujimori, Tomohiro
Masuda, Takahiro
Higuchi, Teruhiko
Vieta i Pascual, Eduard, 1963-
Keywords: Trastorn bipolar
Administració de medicaments
Manic-depressive illness
Administration of drugs
Issue Date: 22-Aug-2020
Publisher: Wiley
Abstract: Aim:Previous studies conducted primarily in the USA and Europe have demonstrated the efficacy and safety of lurasidone 20-120 mg/day for the treatment of bipolar I depression. The aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar I depression among patients from diverse ethnic backgrounds, including those from Japan. Methods:Patients were randomly assigned to double‐blind treatment for 6 weeks with lurasidone, 20-60 mg/day (n = 184) or 80-120 mg/day (n = 169), or placebo (n = 172). The primary end‐point was change from baseline to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). Results:Lurasidone treatment significantly reduced mean MADRS total scores from baseline to Week 6 for the 20-60‐mg/day group (−13.6; adjusted P = 0.007; effect size = 0.33), but not for the 80-120‐mg/day group (−12.6; adjusted P = 0.057; effect size = 0.22) compared with placebo (−10.6). Treatment with lurasidone 20-60 mg/day also improved MADRS response rates, functional impairment, and anxiety symptoms. The most common adverse events associated with lurasidone were akathisia and nausea. Lurasidone treatments were associated with minimal changes in weight, lipids, and measures of glycemic control. Conclusion: Monotherapy with once daily doses of lurasidone 20-60 mg, but not 80-120 mg, significantly reduced depressive symptoms and improved functioning in patients with bipolar I depression. Results overall were consistent with previous studies, suggesting that lurasidone 20-60 mg/day is effective and safe in diverse ethnic populations, including Japanese.
Note: Reproducció del document publicat a:
It is part of: Psychiatry and Clinical Neurosciences, 2020, vol. 74, num. 12, p. 635-644
Related resource:
ISSN: 1323-1316
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
703372.pdf320.39 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons